Inovio, a biotechnology firm that develops electroporation-based systems for in vivo gene and bio-molecule delivery, said this week that it has appointed David Pyrce as its chief business officer.
Pyrce comes to Inovio from Vical, where he served as vice president of corporate development. Prior to that, he was general partner at Bear Creek Capital Management and served as vice president and senior healthcare analyst at First Security, Van Kasper & Co.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
